We collected large GWAS studies of MG patients and identified variants in MHC class II locus, protein tyrosine phosphatase nonreceptor type 22 (PTPN22), TNFAIP3 interacting protein 1 (TNIP1)36, cytotoxic T-lymphocyte–associated protein 4 gene (CTLA4)37, combining with the predisposing gene of EOMG including HLA-DRA, HLA-DR3, HLA-B8, HLA-DPB1, HLA-DQB1, HLA-DQA1, CD86, AKAP12, VAV1, TNFSF13B (B-cell activating factor, BAFF), and TNF37–40. This evidence concerns the gene HLA-DRA and myasthenia gravis.